
GRAS Safety Determination Assistant
Build defensible GRAS safety determinations with synthesized scientific evidence and FDA compliance
What You Can Do
You can accelerate GRAS dossier development by synthesizing complex scientific evidence into coherent safety narratives that satisfy FDA 21 CFR 170.30 requirements. This skill guides you through evaluating common use history, building expert consensus documentation, and anticipating regulatory questions—transforming technical data into defensible GRAS determinations that reduce submission delays and increase approval likelihood.
Features
organize and summarize peer-reviewed studies into evidence hierarchies supporting safety claims
determine whether common use history, expert consensus, or qualified expert review applies to your ingredient
structure expert qualifications, conflict-of-interest disclosures, and consensus statements meeting FDA expectations
identify likely regulatory concerns and prepare preemptive responses based on submission category and ingredient complexity
convert technical data into compelling risk-benefit arguments that satisfy regulatory reviewers
analyze published GRAS determinations to benchmark documentation approaches and identify precedent arguments
pinpoint missing studies or evidence needed to strengthen your determination before FDA submission
produce submission readiness checklists aligned with specific GRAS notification pathways
Example Output
Example 1: Scientific Evidence Synthesis You provide a list of 15 studies on your food additive. Claude generates:
- Evidence hierarchy ranking studies by relevance and quality
- Key findings table with dosage, populations, and safety outcomes
- Identified knowledge gaps and areas of consensus
- Proposed narrative: "Five high-quality in vivo studies at consumption-relevant doses demonstrate no adverse effects..."
Example 2: Expert Consensus Documentation You describe your expert panel composition. Claude produces:
- Recommended expert qualifications checklist
- Conflict-of-interest disclosure template
- Consensus statement framework addressing safety margins and sensitivity populations
- FDA question: "How did your panel address neonatal vs. adult susceptibility?" with suggested response structure
Example 3: Regulatory Gap Analysis You upload preliminary literature review. Claude identifies:
- Missing toxicology endpoints (reproduction, developmental, chronic)
- Insufficient sub-populations (pediatric, geriatric, immunocompromised)
- Proposed studies to strengthen determination before submission
What's Included
- SKILL.md instruction file: full GRAS determination methodology and regulatory framework
- GRAS Dossier Template: structured outline for organizing evidence by regulatory requirement
- Expert Panel Documentation Checklist: qualifications, disclosures, and consensus statement standards
- Scientific Evidence Synthesis Framework: literature review organization and risk assessment hierarchy
- FDA Response Template: anticipated questions with response structure examples for each GRAS pathway
Who It's For
- Food regulatory specialists preparing GRAS notifications and FDA submissions
- Food scientists evaluating safety data for novel ingredients and processing aids
- Product development managers conducting preliminary safety assessments before formal regulatory review
- Compliance officers managing regulatory dossiers and FDA correspondence
- Food company counsel coordinating GRAS determinations with scientific and regulatory teams
Best For
- Building comprehensive GRAS safety dossiers for FDA submission
- Synthesizing multi-study scientific literature into coherent safety narratives
- Structuring expert consensus documentation and panel qualification records
- Anticipating FDA questions and preparing preemptive regulatory responses
- Evaluating whether common use history or expert consensus pathways apply to your ingredient
- Identifying data gaps and recommending additional safety studies before submission
- Training internal teams on GRAS regulatory requirements and documentation standards







